The MPN-SAF Total Symptom Score

What Is the MPN-SAF TSS?

The MPN-SAF Total Symptom Score (MPN-SAF TSS), also known as the MPN-10, is a short, patient-reported questionnaire used to measure how much a myeloproliferative neoplasm (MPN) is affecting a person day to day. It grew out of the longer 18-item Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF), which researchers validated in an international patient cohort in 2011 [1]. A year later, investigators distilled that longer form into ten of its most clinically meaningful items, creating the streamlined TSS that clinics and trials use today [2]. The ten items cover fatigue, concentration problems, early satiety, inactivity, night sweats, itching, bone pain, abdominal discomfort, unintentional weight loss, and fever. Each item is self-rated on a 0-to-10 scale, from "absent" to "as bad as you can imagine." Hematologists, hematology-oncology nurses, and clinical trial teams use the MPN-SAF TSS to establish a symptom baseline at diagnosis, track how a patient responds to treatment over time, and standardize symptom reporting across multi-center studies.

Why Symptom Scoring Matters in MPNs

Essential thrombocythemia, polycythemia vera, and primary myelofibrosis are chronic diseases. Blood counts can look reassuring on paper while a patient still feels drained by fatigue, night sweats, or early satiety from an enlarged spleen. Symptom burden does not always move in step with the numbers on a complete blood count. Because MPN treatment goals include quality of life alongside blood count control and thrombosis prevention, clinicians need a validated, repeatable way to capture how the patient is actually doing. The MPN-SAF TSS fills that gap. It correlates well with broader quality-of-life measures, including the EORTC QLQ-C30 [2], and it has become a standard secondary endpoint in myelofibrosis drug trials, including the pivotal studies for ruxolitinib and momelotinib.

In recent years, the MPN-SAF TSS has been widely adapted into electronic Patient-Reported Outcomes (ePROs) and integrated directly into digital health apps and telemedicine portals, allowing for real-time symptom monitoring between clinic visits. Furthermore, modern clinical practice increasingly uses the tool to identify specific 'symptom phenotypes' by grouping items to see if a patient suffers predominantly from cytokine-driven inflammation (e.g., fatigue, sweats, fever), splenomegaly (e.g., early satiety, abdominal pain), or microvascular issues (e.g., itching, bone pain), which helps further personalize targeted therapies [8].

How the Score Is Calculated

Patients complete all ten items on a 0-to-10 scale. The total score is the simple sum of the ten items, giving a possible range of 0 to 100, where a lower score means a lower symptom burden [3]. A mathematical scaling factor is only applied if a patient leaves one or more items blank [4]. In some clinical trial protocols, the fatigue item is drawn specifically from the Brief Fatigue Inventory to keep the measure consistent with earlier fatigue research, but the scoring logic remains the same [5].

A few technical points worth knowing:

• If a patient completes 6 to 9 of the 10 items, some protocols allow the score to be estimated by averaging the completed items and multiplying by 10 [4].
• If 5 or fewer items are completed, the score is generally considered missing rather than estimated [4].
• The score is intended to be repeated at intervals (for example, at each clinic visit or trial cycle) so that the trend, not a single value, is what guides interpretation.

Interpreting the Results

There is no single official cutoff that separates "mild" from "severe" MPN symptom burden, but validation studies and clinical trial practice offer useful reference points.

Individual item severity. For any single symptom item scored 0–10, a score of 0 means the symptom is absent. Scores of 4–6 are generally considered moderate, and scores of 7 or higher are considered severe [6]. This item-level grading is useful for pinpointing which specific symptom is driving distress, such as isolated severe itching in polycythemia vera or severe early satiety in myelofibrosis with a large spleen.

Total score context. In the original international validation cohort of over 1,400 patients, the mean total score was around 21 out of 100, with meaningful differences by subtype: essential thrombocythemia patients scored lowest (mean around 19), polycythemia vera patients intermediate (mean around 22), and myelofibrosis patients highest (mean around 25) [2]. This pattern reflects the more advanced marrow disease typically seen in myelofibrosis.

Response to treatment. Rather than fixed severity bands, the MPN-SAF TSS is most often used to track change over time. In myelofibrosis clinical trials, a 50% or greater reduction in TSS from baseline is a widely used and clinically meaningful threshold for a symptom response to therapy [7]. Trials typically only assess patients for this response if their baseline TSS is high enough for a meaningful reduction to be possible, often requiring a baseline score of at least 10.

Direction matters more than a single number. A rising score over consecutive visits should prompt a clinician to look for disease progression, an enlarging spleen, or a complication such as infection, even if blood counts appear stable. A falling score after starting a JAK inhibitor or interferon supports that the treatment is working from the patient's perspective, not just on paper.

Case Scenarios

Scenario 1: Baseline Assessment & Missing Data in PV

A 58-year-old woman is newly diagnosed with polycythemia vera. Her hematocrit is well-controlled after phlebotomy, but she complains of intense itching after warm showers. You ask her to complete the MPN-10 in the waiting room. She scores her symptoms as follows: Fatigue (6), Itching (8), Concentration problems (4), Inactivity (2), Night sweats (0), Bone pain (0), Unintentional weight loss (0), and Fever (0). She accidentally leaves "Early satiety" and "Abdominal discomfort" blank.

Calculator Exercise: What is her total score?

Clinical Interpretation: Because she completed at least 6 items (she completed 8), her score can still be calculated. The calculator averages her answered items and multiplies by 10, resulting in a score of 25. While her total score is mild, the itching item alone scores an 8 (severe). This pattern tells the clinical team that her overall burden is driven by one dominant symptom, guiding a targeted conversation about therapies like antihistamines or interferon rather than assuming diffuse symptom involvement.

---

Scenario 2: Monitoring response to a JAK inhibitor in myelofibrosis

A 66-year-old man with high-risk primary myelofibrosis is starting ruxolitinib. At baseline, he scores his symptoms: Fatigue (7), Early satiety (8), Abdominal discomfort (7), Night sweats (6), Inactivity (5), Concentration (4), Itching (2), Bone pain (3), Weight loss (0), and Fever (0). At his Week 24 follow-up visit, his symptoms have improved significantly. He now scores Fatigue (4), Early satiety (3), Abdominal discomfort (2), Night sweats (1), Inactivity (2), Concentration (2), Itching (1), Bone pain (1), Weight loss (0), and Fever (0).

Calculator Exercise: Did this patient achieve a standard symptom response?

Clinical Interpretation: His baseline score was 42. At Week 24, his score dropped to 16. Because his score dropped by more than 50% from baseline, he meets the standard clinical trial criteria for a meaningful symptom response. This reinforces that the medication is working well from the patient's perspective, even if his blood counts have only changed modestly.

---

Scenario 3: A rising score prompting further workup

A 71-year-old woman with longstanding essential thrombocythemia (ET) has had stable, low MPN-10 scores (consistently around 10) for several years on hydroxyurea. At today's routine visit, her raw scores are: Fatigue (7), Night sweats (6), Unintentional weight loss (5), Bone pain (6), Fever (3), Concentration (4), Early satiety (3), and 0 for the remaining three items.

Calculator Exercise: Calculate her current score. What should you do next?

Clinical Interpretation: Her score has climbed dramatically to 34, driven by new "B-symptoms" (night sweats, weight loss, fever) and bone pain. Even though her platelet count on today's lab work is only mildly elevated and looks "stable," this steep symptom trajectory raises a major red flag for disease transformation (such as progression to secondary myelofibrosis). This should prompt a repeat bone marrow biopsy. This illustrates why the MPN-10 must be tracked longitudinally.

Limitations of the Scoring System

The MPN-SAF TSS is well validated, but it is not without weaknesses.

It is subjective by design. Because the MPN-SAF TSS is a self-report tool, scores reflect how a patient perceives and reports symptoms rather than an objective physical measurement. Mood, health literacy, cultural background, and even the time of day can shift how a symptom is rated. Two patients with similar disease burden may score quite differently.

Recall windows are not always consistent. Some versions of the form ask patients to rate their worst symptom over the last 24 hours, while others use a 7-day recall period. These are not always directly interchangeable, which can complicate comparisons across studies or even across visits if the version changes mid-treatment.

Items are nonspecific to MPNs. Fatigue, night sweats, and weight loss can be driven by anemia, infection, thyroid disease, depression, poor sleep, or normal aging, not just the underlying MPN. A rising score should prompt further assessment rather than an automatic assumption of disease progression.

The standard response threshold has statistical limitations. Clinical trials commonly use a 50% or greater reduction in TSS (TSS50) as a dichotomous marker of response. This threshold is useful for standardizing trial endpoints, but treating response as a simple yes-or-no cutoff discards information. Emerging evidence suggests that analyzing the TSS as a continuous variable may capture real treatment effects more sensitively than the TSS50 cutoff alone.

Missing-item handling varies. Protocols differ in how they manage incomplete forms. Some average the completed items and scale up to estimate a full score, while others discard the visit entirely if too many items are missing. This means scores are not always calculated identically across different studies or trial sponsors.

Possible floor and ceiling effects. Patients with minimal symptoms tend to cluster near a score of 0, while patients with severe, multi-symptom disease can cluster near the top of the scale. This clustering can make it harder for the tool to detect small but clinically real changes at either extreme of the range.

A single severe symptom can be diluted. Because the total score is a sum across ten items, one intensely distressing symptom, such as intractable pruritus, can be averaged out by otherwise mild scores elsewhere. The total may look only moderately elevated even when one specific symptom is severely affecting the patient's quality of life. Reviewing item-level scores alongside the total helps avoid missing this.

It does not directly measure spleen size or other physical findings. Symptom burden and spleen response do not always move together, so the TSS is typically interpreted alongside physical examination or imaging rather than as a stand-alone marker of disease status.

Completion burden. Repeated administration, sometimes weekly in trials, can be tiring for patients who are already dealing with a heavy symptom load, which may affect completion rates or the consistency of reporting over time.

Disclaimer: This article is intended for educational and informational purposes only. It is not intended to be a substitute for informed professional medical advice, diagnosis, or treatment. While the information presented here is derived from credible medical sources and is believed to be accurate and up-to-date, it is not guaranteed to be complete or error-free. See additional information.

References

1. Scherber, R., Dueck, A. C., Johansson, P., Barbui, T., Barosi, G., Vannucchi, A. M., Passamonti, F., Andreasson, B., Ferarri, M. L., Rambaldi, A., Samuelsson, J., Birgegard, G., Tefferi, A., Harrison, C. N., Radia, D., & Mesa, R. A. (2011). The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. Blood, 118(2), 401–408. https://doi.org/10.1182/blood-2011-01-328955
2. Emanuel, R. M., Dueck, A. C., Geyer, H. L., Kiladjian, J. J., Slot, S., Zweegman, S., te Boekhorst, P. A., Commandeur, S., Schouten, H. C., Sackmann, F., Kerguelen Fuentes, A., Hernández-Maraver, D., Pahl, H. L., Griesshammer, M., Stegelmann, F., Doehner, K., Lehmann, T., Bonatz, K., Reiter, A., Boyer, F., … Mesa, R. A. (2012). Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30(33), 4098–4103. https://doi.org/10.1200/JCO.2012.42.3863
3. Geyer, H. L., & Mesa, R. A. (2014). Therapy for myeloproliferative neoplasms: when, which agent, and how?. Blood, 124(24), 3529–3537. https://doi.org/10.1182/blood-2014-05-577635
4. Christensen, S. F., Scherber, R. M., Mazza, G. L., Dueck, A. C., Brochmann, N., Andersen, C. L., Hasselbalch, H. C., Mesa, R. A., & Geyer, H. L. (2021). Tobacco use in the Myeloproliferative neoplasms: symptom burden, patient opinions, and care. BMC cancer, 21(1), 691. https://doi.org/10.1186/s12885-021-08439-7
5. Langlais, B. T., Mazza, G. L., Kosiorek, H. E., Palmer, J., Mesa, R., & Dueck, A. C. (2021). Validation of a Modified Version of the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score. Journal of hematology, 10(5), 207–211. https://doi.org/10.14740/jh914
6. Găman, M.-A., Scherber, R. M., Ursuleac, I., Crişan, A. M., Bădeliţă, S. N., Ionescu, B. O., Ghiaur, A. E., Brînză, M., Pîrciulescu, N., Lascăr, T. O., Diaconu, C. C., Găman, A. M., & Coriu, D. (2024). Translation, Cultural Adaptation, and Validation into Romanian of the Myeloproliferative Neoplasm Symptom Assessment Form—Total Symptom Score (MPN-SAF TSS or MPN-10) Questionnaire. Journal of Clinical Medicine, 13(11), 3284. https://doi.org/10.3390/jcm13113284
7. Verstovsek, S., Gerds, A. T., Vannucchi, A. M., Al-Ali, H. K., Lavie, D., Kuykendall, A. T., Grosicki, S., Iurlo, A., Goh, Y. T., Lazaroiu, M. C., Egyed, M., Fox, M. L., McLornan, D., Perkins, A., Yoon, S. S., Gupta, V., Kiladjian, J. J., Granacher, N., Lee, S. E., Ocroteala, L., … MOMENTUM Study Investigators (2023). Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study. Lancet (London, England), 401(10373), 269–280. https://doi.org/10.1016/S0140-6736(22)02036-0
8. Geyer, H. L., Scherber, R. M., Dueck, A. C., Kiladjian, J. J., Xiao, Z., Slot, S., Zweegman, S., Sackmann, F., Fuentes, A. K., Hernández-Maraver, D., Döhner, K., Harrison, C. N., Radia, D., Muxi, P., Besses, C., Cervantes, F., Johansson, P. L., Andreasson, B., Rambaldi, A., Barbui, T., … Mesa, R. A. (2014). Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients. Blood, 123(24), 3803–3810. https://doi.org/10.1182/blood-2013-09-527903